HDAC inhibitors effectively induce cell type-specific differentiation in human glioblastoma cell lines of different
Irina Svechnikova1, Per M Almqvist, Tomas J Ekström
1Department of Woman and Child Health, Karolinska Institutet, Pediatric Endocrinology Unit, Q2:08, Karolinska University and Hospital, S-171 76 Stockholm, Sweden. irina.svechnikova@ki.se
Abstract:
The anti-neoplastic effects of histone deacetylase inhibitors (HDACi), Trichostatin A (TSA) and 4-phenylbutyrate (4-PB) on the human glioblastoma cell lines GBM-29, U-343 MG and U-343 MGa Cl. 2:6 were investigated. TSA and 4-PB induced apoptosis in the three cell lines in a dose- and time-dependent manner. Whereas caspase-3 activation was detected in all three cell lines, U-343 MG cells were more sensitive to the apoptotic effect of HDACi compared with U-343 MGa Cl. 2:6. TSA and 4-PB induced differentiation in the three cell lines, each cell line developing unique phenotypic characteristics. During long-term treatment with a low dose of HDACi U-343 MGa Cl. 2:6 cells developed an astrocytic morphology with expression of glial fibrillary acidic protein (GFAP). GFAP-negative U-343 MG cells changed their morphology in response to HDACi and down-regulated their expression of vimentin. The nestin and vimentin positive GBM-29 cells also showed a morphological differentiation, while the expression of the two malignancy markers decreased. In summary, our results showed that these three glioblastoma cell lines display unique phenotypes and differentiation patterns in response to HDACi.
Insights
Histone deacetylase inhibitors (HDACi), Trichostatin A (TSA) and 4-phenylbutyrate (4-PB), induce apoptosis and differentiation in human glioblastoma cells. These HDAC inhibitors reveal unique cellular responses and differentiation patterns across distinct glioblastoma cell lines.
Area of Science:
- Oncology
- Molecular Biology
- Cell Biology
Background:
- Glioblastoma is an aggressive brain tumor with limited treatment options.
- Histone deacetylase inhibitors (HDACi) are emerging as a promising class of anti-cancer agents.
- Understanding the differential effects of HDACi on glioblastoma cell lines is crucial for targeted therapy development.
Purpose of the Study:
- To investigate the anti-neoplastic effects of Trichostatin A (TSA) and 4-phenylbutyrate (4-PB) on human glioblastoma cell lines.
- To analyze the induction of apoptosis and differentiation by HDACi in different glioblastoma cell lines.
- To characterize the unique phenotypic and differentiation responses of GBM-29, U-343 MG, and U-343 MGa Cl. 2:6 cells to HDACi treatment.
Main Methods:
- Treatment of human glioblastoma cell lines (GBM-29, U-343 MG, U-343 MGa Cl. 2:6) with HDAC inhibitors (TSA and 4-PB).
- Assessment of apoptosis induction using caspase-3 activation.
- Evaluation of cellular differentiation through morphological changes and expression analysis of specific markers (GFAP, vimentin, nestin).
Main Results:
- TSA and 4-PB induced apoptosis in all three glioblastoma cell lines in a dose- and time-dependent manner.
- U-343 MG cells exhibited higher sensitivity to HDACi-induced apoptosis compared to U-343 MGa Cl. 2:6 cells.
- HDACi treatment led to unique differentiation patterns in each cell line, including astrocytic differentiation (GFAP expression) in U-343 MGa Cl. 2:6 cells and downregulation of vimentin in U-343 MG cells. GBM-29 cells showed decreased expression of malignancy markers nestin and vimentin.
Conclusions:
- The investigated human glioblastoma cell lines exhibit distinct phenotypes and differentiation responses to HDAC inhibitors.
- HDACi demonstrate anti-neoplastic effects through apoptosis induction and promotion of cellular differentiation in glioblastoma.
- These findings highlight the potential of HDAC inhibitors as therapeutic agents for glioblastoma, with unique cellular responses suggesting tailored treatment strategies.
